HMGB1 and peripheral neuropathy: CIPN, an adverse impact that limits the dosage of commonly used chemotherapy drugs including paclitaxel, oxaliplatin, vincristine, and bortezomib, worths attention, in which HMGB1 is of great significance in the emergence and progression (Fig. 6, HMGB1 and Chemotherapy-Induced Peripheral Neuropathy) (Nishida et al. 2016; Sekiguchi et al. 2018; Sekiguchi and Kawabata 2020; Tsubota et al. 2019; Tsujita et al. 2021).